TPST insider filings

Tempest Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-03. Screen TPST transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 5 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Frederick John W. — Director2——1
Smith Nancy Freda — Director2——1
Horn-Warnock Stephanie — CFO, Treasurer, & Corp Sec.1———

Recent insider filings — Tempest Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2026-11-033Horn-Warnock Stephanie — CFO, Treasurer, & Corp Sec.Holdings only — no transactions reportedEDGAR
2026-11-023Frederick John W. — DirectorHoldings only — no transactions reportedEDGAR
2026-11-024Frederick John W. — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-10-023Smith Nancy Freda — DirectorHoldings only — no transactions reportedEDGAR
2026-10-024Smith Nancy Freda — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-06-234Angel Matthew — CEO and President, Director, 10% ownerPurchase (P): 231,482 @ $2.16 · Purchase (P): 231,482 (derivative) · Purchase (P): 231,482 (derivative)EDGAR
2026-06-174Yee John D. — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-06-084Richey William Drake — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-04-024Trojanowski Justin — Corporate ControllerGrant/award (A): 22,000 (derivative) @ $0EDGAR
2026-04-024Maestas Nicholas — Chief Financial OfficerGrant/award (A): 140,000 (derivative) @ $0EDGAR
2026-03-254Angel Matthew — CEO and President, Director, 10% ownerPurchase (P): 231,482 @ $2.16EDGAR
2026-02-064Angel Matthew — CEO and President, Director, 10% ownerGrant/award (A): 269,621 (derivative) @ $0EDGAR
2026-01-284Simantov Ronit — DirectorGrant/award (A): 1,230 (derivative) @ $0EDGAR
2026-01-284RAAB MICHAEL — DirectorGrant/award (A): 1,230 (derivative) @ $0EDGAR
2026-01-284NICHOL GEOFFREY — DirectorGrant/award (A): 1,230 (derivative) @ $0EDGAR
2026-01-284Pellizzari Christine A — DirectorGrant/award (A): 1,230 (derivative) @ $0EDGAR
2025-01-064Maestas Nicholas — Chief Financial OfficerGrant/award (A): 200,000 (derivative) @ $0EDGAR
2025-01-064Trojanowski Justin — Corporate ControllerGrant/award (A): 30,000 (derivative) @ $0EDGAR
2025-01-064Brady Stephen R — President and CEO, DirectorGrant/award (A): 550,000 (derivative) @ $0EDGAR
2025-01-064Whiting Samuel — Chief Medical OfficerGrant/award (A): 270,000 (derivative) @ $0EDGAR
2024-08-124Versant Venture Capital VI, L.P. — 10% owner
Versant Ventures VI GP, L.P. — 10% owner
Versant Ventures VI GP-GP, LLC — 10% owner
Versant Vantage II, L.P. — 10% owner
Versant Vantage II GP, L.P. — 10% owner
Versant Vantage II GP-GP, LLC — 10% owner
Versant Ventures IV, LLC — 10% owner
Versant Venture Capital IV, L.P. — 10% owner
Versant Side Fund IV, L.P. — 10% owner
Sale (S): 400,000 @ $1.35 · Sale (S): 387,999 @ $1.10EDGAR
2024-07-084Brady Stephen R — President and CEO, DirectorPurchase (P): 35,000 @ $2.11EDGAR
2024-07-034Whiting Samuel — Chief Medical OfficerPurchase (P): 4,672 @ $2.13EDGAR
2024-07-024Trojanowski Justin — Corporate ControllerPurchase (P): 7,500 @ $2.16EDGAR
2024-06-144Simantov Ronit — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2024-06-144RAAB MICHAEL — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2024-06-144NICHOL GEOFFREY — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2024-06-144Pellizzari Christine A — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2024-01-054Brady Stephen R — President and CEO, DirectorGrant/award (A): 250,000 (derivative) @ $0EDGAR
2024-01-054Whiting Samuel — Chief Medical OfficerGrant/award (A): 100,000 (derivative) @ $0EDGAR
2024-01-054Trojanowski Justin — Principal Accounting OfficerGrant/award (A): 26,500 (derivative) @ $0EDGAR
2024-01-054Maestas Nicholas — VP of Strategy and FinanceGrant/award (A): 40,000 (derivative) @ $0EDGAR
2023-10-134Brady Stephen R — President and CEO, DirectorGrant/award (A): 725,000 (derivative) @ $0EDGAR
2023-10-134Trojanowski Justin — Corporate ControllerGrant/award (A): 55,000 (derivative) @ $0EDGAR
2023-10-134Whiting Samuel — Chief Medical OfficerGrant/award (A): 325,000 (derivative) @ $0EDGAR
2023-10-134Maestas Nicholas — VP of Strategy and FinanceGrant/award (A): 100,000 (derivative) @ $0EDGAR
2023-06-204Simantov Ronit — DirectorGrant/award (A): 8,200 (derivative) @ $0EDGAR
2023-06-204RAAB MICHAEL — DirectorGrant/award (A): 8,200 (derivative) @ $0EDGAR
2023-06-204NICHOL GEOFFREY — DirectorGrant/award (A): 8,200 (derivative) @ $0EDGAR
2023-06-204Pellizzari Christine A — DirectorGrant/award (A): 8,200 (derivative) @ $0EDGAR
2023-01-054Whiting Samuel — Chief Medical OfficerGrant/award (A): 69,700 (derivative) @ $0EDGAR
2023-01-054Dubensky Thomas W. — President, DirectorGrant/award (A): 102,700 (derivative) @ $0EDGAR
2023-01-054Brady Stephen R — Chief Executive Officer, DirectorGrant/award (A): 177,300 (derivative) @ $0EDGAR
2023-01-054Maestas Nicholas — VP of Strategy and FinanceGrant/award (A): 38,425 (derivative) @ $0EDGAR
2023-01-054Trojanowski Justin — Corporate ControllerGrant/award (A): 20,300 (derivative) @ $0EDGAR
2022-10-044Trojanowski Justin — Corporate ControllerGrant/award (A): 2,500 (derivative) @ $0EDGAR
2022-06-224Simantov Ronit — DirectorGrant/award (A): 3,500 (derivative) @ $0EDGAR
2022-06-224RAAB MICHAEL — DirectorGrant/award (A): 3,500 (derivative) @ $0EDGAR
2022-06-224NICHOL GEOFFREY — DirectorGrant/award (A): 3,500 (derivative) @ $0EDGAR
2022-06-224Pellizzari Christine A — DirectorGrant/award (A): 3,500 (derivative) @ $0EDGAR

Recent 8-K events — Tempest Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-208-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-11-168-K5.07 — Submission of Matters to a Vote of Security Holders
8.01 — Other Events
EDGAR
2026-11-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-128-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-108-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-11-068-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-10-308-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-10-208-K5.07 — Submission of Matters to a Vote of Security Holders
8.01 — Other Events
EDGAR
2026-10-198-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-288-K1.01 — Entry into a Material Definitive Agreement
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR

Registration filings — Tempest Therapeutics, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=TPST returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs